Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Oncoimmunology

• Publication date

  2018-02-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/2162402X.2017.1381813PMID 29308301PMCID PMC5749624
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

  2016cited by this paper
• Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients

  2015influential reference
• NK cells and interferons.

  2015cited by this paper
• The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma

  2015cited by this paper
• IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy

  2015cited by this paper
• NKG2D Receptor and Its Ligands in Host Defense

  2015cited by this paper
• IL‐18‐induced expression of high‐affinity IL‐2R on murine NK cells is essential for NK‐cell IFN‐γ production during murine Plasmodium yoelii infection

  2015cited by this paper
• Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12

  2015cited by this paper
• Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

  2014influential reference
• Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer.

  2014cited by this paper
• IL-2–dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells

  2013influential reference
• Exploiting a natural conformational switch to engineer an Interleukin-2 superkine

  2012cited by this paper
• Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

  2012cited by this paper
• Cutting Edge: A Novel Mechanism Bridging Innate and Adaptive Immunity: IL-12 Induction of CD25 To Form High-Affinity IL-2 Receptors on NK Cells

  2012influential reference
• IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production

  2011cited by this paper
• Mechanisms of NK cell activation: CD4+ T cells enter the scene

  2011cited by this paper
• Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface

  2011cited by this paper
• CD16 cross-linking induces increased expression of CD56 and production of IL-12 in peripheral NK cells.

  2010cited by this paper
• NK Cells as Effectors of Acquired Immune Responses: Effector CD4+ T Cell-Dependent Activation of NK Cells Following Vaccination

  2010cited by this paper
• A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies

  2009cited by this paper
• The Raf Kinase Inhibitor Sorafenib Inhibits JAK–STAT Signal Transduction in Human Immune Cells

  2008cited by this paper
• High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

  2008cited by this paper
• Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.

  2008cited by this paper
• Human natural killer cells.

  2008cited by this paper
• The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor–Positive Tumor Cells is Enhanced By Cytokines

  2007cited by this paper
• Positive and negative regulation of Natural Killer cells: therapeutic implications.

  2006cited by this paper
• The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

  2006cited by this paper
• Human natural killer cell development and biology.

  2006influential reference
• Interleukin-2, interleukin-15, and their roles in human natural killer cells.

  2005cited by this paper
• A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies

  2004cited by this paper
• CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.

  2003cited by this paper
• IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.

  2002cited by this paper
• Natural killer cells contribute to the lethality of a murine model of Escherichia coli infection.

  2002cited by this paper
• Interleukin‐2 enhances the natural killer cell response to Herceptin‐coated Her2 / neu‐positive breast cancer cells

  2001cited by this paper
• Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies.

  2001cited by this paper
• Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

  2001cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• In vivo natural killer cell activities revealed by natural killer cell-deficient mice.

  2000cited by this paper
• NK cell receptors.

  1998cited by this paper
• [Interleukin-2 receptor].

  1997cited by this paper
• Signal transduction during natural killer cell activation: inside the mind of a killer.

  1997cited by this paper
• Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.

  1995cited by this paper
• Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.

  1993cited by this paper
• Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.

  1993cited by this paper
• Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo

  1990cited by this paper
• Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells

  1988cited by this paper
• The interleukin 2 receptor.

  1988cited by this paper
• Natural killer cells: definition of a cell type rather than a function.

  1986cited by this paper
• Response of resting human peripheral blood natural killer cells to interleukin 2

  1984cited by this paper
• Human natural killer cells.

  1979cited by this paper

• Interleukin-12 decorated nanosized semiflexible Immunofilaments enable directed targeting and augmented IFNγ responses of Natural Killer Cells.

  2024cites this paper
• The innate defenders: a review of natural killer cell immunotherapies in cancer

  2024cites this paper
• From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement

  2022cites this paper
• The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

  2021cites this paper
• Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells

  2020cites this paper
• Analysis of chicken intestinal natural killer cells, a major IEL subset during embryonic and early life.

  2020cites this paper
• Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

  2020cites this paper
• Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell

  2020cites this paper
• Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies

  2020cites this paper
• Activating natural killer (NK) cytotoxicity of canine CD5-CD21- cells requires low surface CD5 density NK cells.

  2018cites this paper
• Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors

  2018cites this paper